We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Women with Gestational Diabetes Need Retesting After Pregnancy

By HospiMedica International staff writers
Posted on 12 May 2010
Women who have had gestational diabetes should be retested for diabetes 6 to 12 weeks after the baby is born, and at least every three years after that. Follow-up screening usually consists of a simple blood test.

Generally, steps are taken to manage gestational diabetes during pregnancy for the health of both mother and child. However, many women do not realize that if they have had gestational diabetes they are at increased risk for developing diabetes in the future, and their child is also at increased risk for obesity and type 2 diabetes.

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK; Bethesda MD, USA) and the Office of Research on Women's Health (ORWH; Bethesda, MD, USA) are together promoting awareness of risks attached for mothers and children after pregnancies where there had been gestational diabetes. A special effort was made from May 9-15, 2010, which included Mother's Day in many parts of the world, and [US] National Women's Health Week.

"Many women think that if the follow-up test after the baby is born shows no signs of diabetes, they are in the clear, but that is not the case," said Vivian Pinn, M.D., director of the ORWH. "What many of these moms do not know is that they have a 40 % to 60 % chance of developing diabetes as early as five to 10 years after their baby is born. These women need to know this information and they need to take steps to lower their risk for developing diabetes."

Related Links:
U.S. National Institute of Diabetes and Digestive and Kidney Diseases
Office of Research on Women's Health


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Hybrid Arch Device
Neo EDE
Medical Adhesive
MED 5570U

Channels

Artificial Intelligence

view channel
Image: Coredio’s CPSE is a a software-as-a-medical-device platform designed for use with consumer smartwatches and standard blood pressure cuffs in clinical and home settings under physician supervision (Photo courtesy of Coredio)

AI Platform Supports Noninvasive Remote Hemodynamic Monitoring in Heart Failure

Heart failure remains a leading cause of hospitalization in adults over 65, affecting more than 6.7 million people in the U.S. Clinicians often lose visibility into hemodynamic deterioration once patients... Read more